# Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

> **NCT02194179** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 92 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** NVP XR 400 mg (KCR 25%)
- **DRUG:** NVP XR 400 mg (KCR 20%)
- **DRUG:** NVP XR 300 mg (KCR 25%)
- **DRUG:** NVP XR 300 mg (KCR 20%)
- **OTHER:** high-fat breakfast
- **DRUG:** NVP IR 200 mg (Viramune®)

## Key facts

- **NCT ID:** NCT02194179
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194179, "Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02194179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*